Fatty Liver Index as a Simple and Useful Predictor for 10-year Cardiovascular Disease Risks Determined by Framingham Risk Score in the General Korean Population by 이용제
J Gastrointestin Liver Dis, June 2021 Vol. 30 No 2: 221-226
1) Department of Family 
Medicine, Wonju Severance 
Christian Hospital, Yonsei 
University Wonju College of 
Medicine, Wonju;
2) Department of Medicine, 
Graduate School of Medicine, 
Yonsei University, Seoul;
3) Department of Health 
Promotion, Severance 
Checkup, Yonsei University 
Health System, Seoul;
4) Department of Family 
Medicine, Gangnam Severance 
Hospital, Yonsei University 
College of Medicine, Seoul, 
Republic of Korea
Address for correspondence: 
Yong-Jae Lee MD, MPH, PhD.
Professor, Department of 
Family Medicine 
Yonsei University College of 
Medicine, Gangnam Severance 
Hospital 
211 Eonju-ro, Gangnam-gu, 
Seoul 06273, 





Fatty Liver Index as a Simple and Useful Predictor for 10-year 
Cardiovascular Disease Risks Determined by Framingham Risk 
Score in the General Korean Population
Tae-Ha Chung1,2, Jong-Koo Kim1, Ji-Hye Kim3, Yong-Jae Lee4
INTRODUCTION
Fatty liver disease (FLD) 
includes non-alcoholic fatty 
liver disease (NAFLD) and 
alcoholic fatty liver disease 
(AFLD) [1], which are the 
most common chronic liver 
diseases encountered in clinical 
practice [2]. Non-alcoholic 
fatty liver disease is defined 
by the accumulation of fat in 
more than 5% of the liver by 
weight, with little or no alcohol 
consumption, and AFLD is 
developed by consuming greater 
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ABSTRACT
Background & Aims: The fatty liver index (FLI) is a simple and non-invasive method for the diagnosis of 
fatty liver disease with an increased risk of cardiovascular disease (CVD) as well as liver-related mortality. We 
examined the association between FLI and 10-year CVD risk as determined by the Framingham risk score.
Methods: This cross-sectional study included 7,240 individuals aged 30 to 69 years who underwent a health 
examination between 2015 and 2017. The FLI was calculated using an algorithm based on triglyceride, 
γ-glutamyltransferase, body mass index (BMI), and waist circumference. Multiple linear and logistic regression 
analyses were performed to assess independent relationships between the FLI and Framingham risk score 
after adjusting for confounding variables. 
Results: The overall prevalence of fatty liver disease among study participants as assessed by an FLI ≥ 60 was 
19.7%. Compared with non-hepatic steatosis (FLI < 30), the odds ratio (95% confidence interval) for a high 
Framingham 10-year CVD risk ≥ 10% in individuals with hepatic steatosis (FLI ≥ 60) was 2.56 (1.97–3.33) 
after adjusting for age, gender, fasting plasma glucose, high-density and low-density lipoprotein cholesterol, 
blood pressure, C-reactive protein, regular exercise, alcohol-drinking, and current smoking.
Conclusions: The FLI was positively and independently associated with a Framingham 10-year CVD risk 
in the general Korean population. Our findings suggest that the FLI, a simple, useful, and economical index, 
may be an indicator of CVD events.
 
Key words: fatty liver index – insulin resistance – cardiovascular disease – Framingham risk score.
Abbreviations: AFLD: alcoholic fatty liver disease; ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; BMI: body mass index; CRP: C-reactive protein; CVD: cardiovascular disease; DBP: 
diastolic blood pressure; FLD: fatty liver disease; FLI: fatty liver index; HbA1c: glycated hemoglobin; HDL: 
high-density lipoprotein; IHD: ischemic heart disease; LDL: low-density lipoprotein; NAFLD: non-alcoholic 
fatty liver disease; SBP: systolic blood pressure; TG: triglycerides; WC: waist circumference. 
than 30 g/day of alcohol [3]. Although these forms of FLD are 
defined in medical terms, with the concept of “dual-etiology 
fatty liver disease,” both NAFLD and AFLD have similar 
pathophysiology and histological features, from steatosis to 
cirrhosis [4].
An increasing body of epidemiological evidence suggests 
that FLD predicts not only liver-related diseases but also 
cardiovascular disease (CVD), which is a leading cause of 
premature mortality and a substantial determinant of a lower 
quality of life [5, 6]. Previous observational studies have been 
conducted to investigate the link between FLD and incident 
CVD, but they have shown inconsistent results. A recent 
study found that NAFLD was not associated with increased 
incident acute myocardial infarction or stroke after adjusting 
for established CVD factors [7]. On the other hand, another 
cohort study concluded that NAFLD was associated with 
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increased incidence of myocardial infarction independently 
of established risk factors [8].
Early identification of individuals at higher risk for FLD 
may allow for the application of preventive strategies that can 
slow the development and progression of both liver-related 
diseases and CVD. The traditional diagnosis of FLD requires 
various techniques such as liver ultrasonography, magnetic 
resonance, and biopsy. More recently, the fatty liver index (FLI), 
based on body mass index (BMI), waist circumference (WC), 
triglycerides (TG), and γ-glutamyltransferase [9], has emerged 
as a simple and economical alternative for mass screening for 
hepatic steatosis with reasonable sensitivity and specificity [10].
Although several previous studies have shown an 
association between FLD and CVD risks, most diagnostic 
methods of FLD are based on liver ultrasonography, magnetic 
resonance, or biopsy. These diagnostic tools have limited 
applicability in general clinical practice. Therefore, we 
examined the association between FLI and CVD risk in an 




Volunteers in a retrospective, cross-sectional study 
underwent medical examinations at the at the Severance Health 
Promotion Center, Severance Hospital, Yonsei University 
Health System, in Seoul, Korea, between 2015 and 2017. The 
study was conducted by the ethical principles of the Declaration 
of Helsinki and approved by the Institutional Review Board 
of Yonsei University College of Medicine. We retrospectively 
reviewed the medical records of 26,176 participants between 
the ages of 12 and 92 years. We excluded participants who met 
one or more of the following criteria: missing anthropometric 
and questionnaire data; aged < 30 and ≥ 70 years; a positive 
test for hepatitis B antigens or hepatitis C antibodies; above 
twice the upper normal limits for aspartate aminotransferase 
(AST) or alanine aminotransferase (ALT); leukocyte count ≥ 
11,000 cells/μL; high sensitive C- reactive protein (CRP) ≥ 10 
mg/L; a history of ischemic heart disease, stroke, any cancer, 
thyroid, respiratory, renal, hepatobiliary, or rheumatologic 
disease; and failure to fast for 8 h prior to testing. After these 
exclusions (n=18,936), a total of 7,240 participants aged 30 to 
69 years old were included in the final analysis.
Data collection
Each participant completed a questionnaire about lifestyle 
and medical history. Self-reported cigarette smoking, alcohol 
consumption, and physical activity characteristics were 
extracted from the questionnaires. The smoking statuses 
were nonsmoker, ex-smoker, and current smoker. Questions 
regarding alcohol intake included frequency on a weekly basis. 
Current alcohol consumption was defined as drinking alcoholic 
beverages two or more times per week. Participants were asked 
about their physical exercise on a weekly basis, and regular 
exercise was defined as exercising more than 3 times per week 
with moderate-to-vigorous intensity. Body mass and height were 
measured to the nearest 0.1 kg and 0.1 cm, respectively, with 
the participants wearing light indoor clothing without shoes. 
Body mass index was calculated as the weight in kilograms 
divided by the square of the height in meters (kg/m2). Systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) were 
measured using the patient’s right arm with a standard mercury 
sphygmomanometer (Kensei Industry Co., Ltd. Japan). The 
presence of hypertension was defined as SBP ≥ 140 mmHg, DBP 
≥ 90 mmHg, taking antihypertensive medication, or diagnosis 
by a physician. The presence of diabetes was determined as a 
fasting glucose of 126 mg/dL, glycated hemoglobin (HbA1c) of 
6.5% or above, taking antidiabetic medication, or diagnosis by 
a physician. The presence of dyslipidemia was determined as 
total cholesterol ≥ 240 mg/dL or low-density lipoprotein (LDL) 
cholesterol ≥ 160 mg/dL or TG ≥ 150 mg/dL or high-density 
lipoprotein (HDL) cholesterol < 40 mg/dL in men and < 50 mg/
dL in women, taking antidyslipidemic medication, or diagnosis 
by a physician. Blood samples were obtained after 8 hours of 
overnight fasting. Leukocyte counts were measured using the 
ADVIA 2120i Hematology System Clinical (Siemens Healthcare 
Diagnostic, Inc, NY). Fasting plasma glucose, total cholesterol, 
triglyceride, LDL cholesterol, HDL cholesterol, AST, ALT, and 
CRP were measured with the ADVIA 1800 Clinical Chemistry 
System (Siemens Healthcare Diagnostic, Inc, NY). 
Fatty liver index
The FLI score was calculated using the algorithm based on 
TG, γ-glutamyltransferase, BMI, and WC as follows: 
FLI = (e [0.953 × ln(TG) + 0.139 × BMI + 0.718 × ln(GGT) + 0.053 × WC - 15.745])/
(1+ e [0.953 × ln(TG) + 0.139 × BMI + 0.718 × ln(GGT) + 0.053 × WC - 15.745]) x 100
Possible FLI scores range from 0 to 100, with subjects 
categorized as having non-hepatic steatosis (FLI < 30) or 
hepatic steatosis (FLI ≥ 60) [9]. Also, we defined the middle 
scores (FLI 30–59) as an “intermediate group” in this study.
10-year CVD risk 
The Framingham risk score is a useful predictor of an 
individual’s risk of experiencing a severe cardiovascular event 
for the next 10 years. The Framingham risk score prediction 
algorithm that served as the basis for the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP-ATP III) 
risk-scoring algorithm used six risk factors, including gender, 
age, total cholesterol, HDL cholesterol, SBP (points assigned for 
blood pressure depend on the treatment of hypertension), and 
smoking status. Table I showed that total scores were obtained 
by summing the points for each risk factor, and the 10-year 
CVD risk in percentage was divided by the total points [11]. 
The estimated risk for 10‐year CVD was classified as low (< 
10%) and intermediate or high (≥ 10%). A high Framingham 
10-year CVD risk score was defined as ≥ 10% in this study.
Statistical analysis
Normal distribution was evaluated by determining 
skewness using a Kolmogorov–Smirnov test and AST, ALT, 
CRP, and Framingham 10-years CVD risk levels had skewed 
distributions. FLI was categorized as follows: FLI < 30, 30 ≤ 
FLI ≤ 59, and FLI ≥ 60.
The clinical characteristics of the study population 
according to categorized FLI groups were compared using 
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one-way analysis of variance (ANOVA) or a Kruskal–Wallis 
test for continuous variables according to the normality of 
distributions and chi-square tests for categorical variables. 
Continuous data were presented as mean (standard deviation, 
SD) or median (interquartile range), and categorical data 
were presented as frequencies. The mean values [standard 
deviation (SDs)] of Framingham 10-year CVD risk across the 
categorized FLI per 10 points were evaluated using an ANOVA. 
The odds ratios (ORs) and 95% confidence intervals (CIs) for 
high Framingham 10-year CVD risks were calculated across 
categorized FLI groups using multiple logistic regression 
analysis after adjusting for confounding variables. All analyses 
were conducted using SPSS for Windows (version 25.0; IBM, 
NY, USA). All statistical tests were two-sided, and a p <0.05 
was considered statistically significant.
RESULTS
A flow diagram of the study participants was showed in 
Fig. 1. The clinical characteristics of the subjects are supplied 
in Table II. Among the 7,240 subjects, 3,856 were categorized as 
having non-hepatic steatosis (FLI < 30), 1,955 as intermediated 
(FLI 30–59), and 1,429 as having hepatic steatosis (FLI ≥ 60). 
The overall prevalence of FLD as assessed by FLI ≥ 60 was 
19.7% in the current study participants. The hepatic steatosis 
group (FLI ≥ 60) had the highest mean values of BMI, WC, SBP, 
DBP, fasting plasma glucose, total cholesterol, and leukocyte 
counts, whereas they had the lowest HDL-cholesterol level. 
Members of the hepatic steatosis group (FLI ≥ 60) had the 
highest median values of AST, ALT, CRP, and Framingham 
10-year CVD risks. The percentages of current smoking and 
alcohol-drinking were highest, and hypertension, type 2 
diabetes, and dyslipidemia were most prevalent in the hepatic 
steatosis group (FLI ≥ 60) compared with other groups. 
Fig. 2 shows the mean (SD) Framingham 10-year CVD risk 
according to the categorized FLI per 10 points. The means (SD) 
of Framingham 10-year CVD risks increased gradually by the 
categorized FLI per 10 points (p < 0.001).
Table III presents the results of multiple logistic regression 
analysis to assess the independent relationships between FLI 
and Framingham 10-year CVD risk. Compared with non-
hepatic steatosis (FLI < 30), the OR (95% CI) for a Framingham 
10-year CVD risk    ≥10% in individuals with hepatic steatosis 
(FLI ≥ 60) was 2.56 (1.97–3.33) after adjusting for age, gender, 
fasting plasma glucose, HDL cholesterol, LDL cholesterol, SBP, 
Table I. Estimate of 10-year cardiovascular disease risk for men and women
Men Women
Total points 10-year risk, % Total points 10-year risk, %
< 0 0 < 9 0
0–4 1 9–12 1
5–6 2 13–14 2
7 3 15 3
8 4 16 4
9 5 17 5
10 6 18 6
11 8 19 8
12 10 20 11
13 12 21 14
14 16 22 17
15 20 23 22
16 25 24 27
≥ 17 30 ≥ 25 30
Fig. 1. Flow diagram of the study participants.
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DBP, CRP, regular exercise, alcohol-drinking, and current 
smoking. 
DISCUSSION
In this cross-sectional study, we found that FLI was 
positively and independently associated with the 10-year 
CVD risk in the general Korean population. Our findings are 
consistent with previous results that demonstrated that FLD 
is positively associated with an increased CVD risk in adult 
populations [8, 12].
Motamed et al. [12] conducted a study on 2,804 subjects 
aged 40-74 years from a cohort study of northern Iran. They 
concluded that individuals with NAFLD had a higher risk 
of 10-year CVD events than individuals without NAFLD 
[12]. Moreover, Kim et al. [8] conducted a prospective study 
involving 3,011,588 subjects with no history of CVD who 
underwent health examinations in the Korean National Health 
Insurance System cohort from 2009 to 2011, with a median 
follow-up period of 6 years. The authors concluded that FLI 
has a prognostic value for detecting individuals at a higher 
risk for cardiovascular events [8]. On the other hand, the 
European cohort study reported that the diagnosis of NAFLD 
in current routine care of 17.7 million patients appears not to 
be associated with acute myocardial infarction and stroke risk 
after adjustment for established cardiovascular risk factors [7]. 
The difference in results between countries as above may be due 
to age range, racial characteristics, comorbidities, and sample 
size of the study populations’ racial characteristics. 
Although in the previous studies, there has been a large 
focus on the differentiation between NAFLD and AFLD, it is 
gradually recognized that a large coincide exists between the 
two entities [13]. Recent literature reviews reported that NAFLD 
and AFLD have an overlap in the pathogenic mechanisms 
Table II. Clinical characteristics of the study population according to the fatty liver index (FLI)
Fatty liver index (FLI)
Total FLI (< 30) FLI (30-59) FLI (≥60) p-value
N 7,240 3,856 1,955 1,429
Male (%) 78.5 62.2 95.0 97.7 <0.001
Age (year) 47.8 (9.4) 46.6 (9.7) 49.7 (8.9) 48.3 (8.6) <0.001
Body mass index (kg/m2) 24.2 (3.1) 22.3 (2.1) 25.2 (1.8) 27.8 (2.9) <0.001
Waist circumference (cm) 83.9 (9.9) 77.6 (7.3) 88.1 (5.2) 95.0 (7.7) <0.001
Systolic blood pressure (mmHg) 120.9 (13.5) 116.5 (12.8) 123.7 (12.3) 129.0 (12.0) <0.001
Diastolic blood pressure (mmHg) 79.4 (11.2) 75.5 (10.4) 82.2 (10.1) 86.3 (10.0) <0.001
Fasting plasma glucose (mg/dL) 100.2 (18.6) 95.3 (13.6) 103.4 (18.2) 109.2 (25.1) <0.001
Total cholesterol (mg/dL) 198.0 (34.4) 192.0 (31.7) 201.6 (33.4) 209.3 (39.0) <0.001
LDL-cholesterol (mg/dL) 119.3 (32.4) 113.7 (30.4) 125.7 (31.3) 125.5 (36.3) <0.001
HDL-cholesterol (mg/dL) 53.2 (13.1) 58.1 (13.6) 48.9 (10.5) 46.1 (9.1) <0.001
Aspartate aminotransferase (U/L) 24 (20-29) 22 (19-26) 25 (21-30) 29 (24-37) <0.001
Alanine aminotransferase (U/L) 22 (16-32) 18 (13-23) 26 (20-36) 36 (27-50) <0.001
Leukocyte count (cells/μL) 5,806 (1,457) 5,431 (1,357) 6,056 (1,432) 6,480 (1,436) <0.001
C-reactive protein (mg/L) 0.3 (0.1-0.8) 0.2 (0.1-0.4) 0.3 (0.2-0.9) 0.6 (03-1.6) <0.001
Framingham 10-years CVD risk (%) 5 (2-10) 4 (1-8) 6 (4-12) 8 (5-12) <0.001
Current smoking (%) 27.1 18.9 33.5 40.4 <0.001
Alcohol drinking (%)a 65.3 59.3 69.6 75.6 <0.001
Regular exercise (%)b 58.6 61.0 59.8 50.5 <0.001
Hypertension (%) 29.5 16.5 37.1 54.0 <0.001
Type 2 diabetes (%) 7.4 3.6 9.8 14.5 <0.001
Dyslipidemia (%) 46.6 25.2 59.4 85.7 <0.001
Data are expressed as the mean (SD), median (interquartile range) or percentage. P values were calculated using 1-way 
ANOVA test, Kruskal-Wallis test and chi-square test. aAlcohol drinking ≥two times /week. bRegular exercise ≥three times 
/week.
Fig. 2. The mean (SD) of the Framingham 10-year CVD risk according 
to the categorized FLI per 10 points.
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leading to the trigger of both hepatic inflammation and 
fibrogenic pathways [4, 14]. Furthermore, moderate and heavy 
alcohol consumption, obesity, and metabolic dysfunction are 
synergistic effects on the development of fatty liver disease [15, 
16]. Therefore, NAFLD and AFLD frequently coexist in the 
general clinical setting. Furthermore, a recent international 
consensus suggested metabolic associated fatty liver disease 
(MAFLD) as a novel concept [17]. Lin et al. [18] showed that 
compared with NAFLD, MAFLD is more practical to identify 
FLD patients associated with a high risk of metabolic disease 
progression. In these aspects, we wanted to study the concept 
of “dual-etiology fatty liver disease” without distinguishing 
between NAFLD and AFLD [4]. We also wanted to report the 
results by statically adjusting metabolic parameters and lifestyle 
such as age, BMI, blood pressure, fasting plasma glucose, lipid 
profile, regular exercise, alcohol-drinking, and current smoking.
Several potential mechanisms may explain the positive 
relationships between the FLD and 10-year CVD risk. NAFLD 
is now regarded as a hepatic manifestation of metabolic 
syndrome [19]. Insulin resistance, the core feature of metabolic 
syndrome, may lead to the development of systemic chronic 
low-grade inflammation [20]. In this respect, subclinical 
inflammation can promote adverse CVD events mediated by 
coronary artery atherosclerosis. This pathway can be triggered 
by a pro-inflammatory protein complex and cytokines, such 
as nuclear factor-kB, interleukin-1, interleukin-6, and tumor 
necrosis factor-α [21]. Additionally, insulin resistance can 
alter lipid metabolism, decrease HDL cholesterol, and increase 
triglycerides and fatty acids in the liver [22]. In these cascades, 
oxidative stress triggered by accumulated adipose tissue in the 
liver may play a key role in endothelial dysfunction, leading 
to the accumulation of oxidized LDL cholesterol in the sub-
intimal wall [23]. 
The plausible mechanisms linking elevated FLI to the 
estimated 10-year CVD risk are suggested above, the causal 
relationship between them is still unclear. In a meta-analysis to 
examine the causal relationship between NAFLD and ischemic 
heart disease (IHD) [24], there was a positive association 
between fat deposition in the liver and IHD. However, the 
causal relationship of hepatic steatosis with IHD was not clear. 
Another study showed that NAFLD was significantly associated 
with an incident risk of type 2 diabetes, but not associated 
with incident CVD [25]. These discrepancies are largely due 
to the individual’s lifestyle and genetic factors that can affect 
the development of CVD [26].
Our study had several limitations. First, it had a cross-
sectional design, which suggests that caution should be 
used when making causal and temporal interpretations; 
it is impossible to determine whether FLI is a risk factor 
actively involved in the development of CVD or a bystander 
epiphenomenon. Further large prospective studies are required 
to explain possible associations between FLI and CVD risks. 
Second, because the study participants were volunteers 
undergoing health promotion screenings in a single hospital 
and appeared to be slightly healthier than most of their 
community-based cohorts, the study population may not 
be representative of the general population. Third, because 
this study used secondary data from the health promotion 
center, we could not accurately quantify the amount of alcohol 
consumed and dietetic profile. Finally, we did not consider 
the effects of medicines such as tamoxifen, glucocorticoids, 
and amiodarone in relation to steatohepatitis [27]. Due to the 
nature of a secondary dataset from a health promotion center, 
these variables were not fully adjusted for the statistical models.
Despite these potential limitations, positive associations 
between FLI and Framingham risk score in our study imply 
that FLI may be an independent marker of a 10-year CVD risk 
in the general Korean population. The current findings may be 
a useful additional measure in assessing CVD risk in clinical 
and research settings.
Finally, FLD appears to be an independent factor associated 
with the development of future CVD. In this way, FLD should 
be taken into account when considering CVD prevention. 
FLI is a noninvasive, inexpensive and easy test to calculate, 
which should be accessible for both patients and clinicians 
in the clinical practice. Patients with high FLI values should 
be counseled on the increased risk of developing CVD in the 
future. These patients should also be targeted for an additional 
cardiovascular preventive strategy, with the management of 
comorbidities associated with CVD onset and development.
CONCLUSIONS
The FLI was positively and independently associated with 
the Framingham 10-year CVD risk in the general Korean 
population. Our findings suggest that the FLI, a simple, 
useful, and economical index, may be a useful indicator of 
CVD events. More comprehensive care for improving fatty 
liver might be helpful in preventing the incident CVD risk in 
clinical settings.
Table III. Odds ratios and 95% confidence intervals for high Framingham 10-years CVD risk ≥ 10 % 
according to fatty liver index
Fatty liver index (FLI)
FLI (<30) FLI (30-59) FLI (≥60)
Unadjusted 1.00 (reference) 2.62 (2.32-2.95) 3.43 (3.01-3.91)
Model 1 1.00 (reference) 2.39 (2.06-2.78) 4.46 (3.77-5.28)
Model 2 1.00 (reference) 1.63 (1.38-1.92) 2.64 (2.17-3.21)
Model 3 1.00 (reference) 1.60 (1.28-2.00) 2.56 (1.97-3.33)
Model 1: adjusted for age, sex. Model 2: adjusted for age, sex, fasting glucose, HDL-cholesterol, LDL-
cholesterol, systolic blood pressure, diastolic blood pressure and C-reactive protein. Model 3: adjusted 
for age, sex, fasting glucose, HDL-cholesterol, LDL-cholesterol, systolic blood pressure, diastolic blood 
pressure, C-reactive protein, regular exercise, alcohol drinking and current smoking.
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